OncoSil Medical Ltd · ASX:OSL
OncoSil Medical — Shareholder Meeting (November 2026)
16 slides from OncoSil Medical's shareholder meeting presentation, Nov 18, 2026
Slide 1: Chairman's Address to 2026 Annual General Meeting
ASX Announcement 18 November 2026 For personal use only Chairman’s Address to 2026 Annual General Meeting Sydney, Australia – 18 November 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresect
Slide 2: Chairman's Address (continued)
expanding our label to better align with current standards of care. PANCOSIL demonstrated that percutaneous delivery is both safe and feasible, while interim data from the For personal use only OSPREY registry showed median overall survival of 20.6 and 22.0 months in first-line patients. The Company
Slide 3: Chairman's Address close and About OncoSil Medical
On behalf of the Board, I would like to thank our shareholders for their continued support and confidence, our employees for their dedication and commitment, our clinicians and investigators for advancing the clinical evidence supporting our technology, and our partners for their collaboration throu
Slide 4: Commercial Inflection: Capitalising on global regulatory approvals
rsonal use only AGM Presentation Commercial Inflection: Capitalising on global regulatory approvals and high-margin scalability OncoSil Medical Limited (ASX:OSL) 18 November 2026
Slide 5: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil, OSL or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the inf
Slide 6: Corporate Summary
Corporate Summary Focus Directors / Management A medical device company focused on localised treatments Dr Thomas Duthy Non-Executive Chairman for patients with unresectable locally advanced pancreatic rsonal use only cancer (LAPC) and distal cholangiocarcinoma (dCCA) Nigel Lange CEO & Managing Dire
Slide 7: Unlocking scalable execution in endoscopy and interventional oncology
Unlocking scalable execution in endoscopy and interventional oncology Targeting unresectable Locally Advanced Pancreatic Cancer (uLAPC) and Distal Cholangiocarcinoma (dCCA) rsonal use only OncoSil Medical (ASX:OSL) is an advanced, early commercial-stage global medical technology innovator that has t
Slide 8: Unlocking a A$6.4 billion global market
Unlocking a A$6.4 billion1 global market From regulatory milestones to commercial scalability Key strategic pillars: rsonal use only OncoSil Medical has successfully advanced past the high-risk R&D The transition point and clinical trial phase into a fully approved, commercially executing medical te
Slide 9: The US strategy: High-margin asset execution
The US strategy: High-margin asset execution Maximising value via the US FDA Humanitarian Device Exemption (HDE) pathway US FDA HDE approval grants immediate marketing authorisation for distal rsonal use only cholangiocarcinoma (dCCA) bypassing years of traditional clinical trials to unlock a The st
Slide 10: De-risked pathway to global execution
De-risked pathway to global execution Our message to Shareholders rsonal use only OncoSil Medical is no longer is noa longer story about a story clinical abouttrials clinical andtrials regulatory and regulatory checkboxes—that checkboxes risk - that is behind risk isus. behind Withus. globalglobal W
Slide 11: Established funding channels & expanding the clinical label
Established funding channels & expanding the clinical label Driving commercial adoption via peer-reviewed evidence in uLAPC German G-BA Approval: Formally approved by Federal Joint Committee (Gemeinsammer rsonal use only Bundesausschuss), this legal framework establishes a Coverage with Evidence Dev
Slide 12: A consistent survival signal
A consistent survival signal Exceptional survival profiles validated across multiple tiers of clinical evidence The OncoSil device demonstrates highly consistent performance metrics across all rsonal use only Clinical performance trial frameworks, geographies and delivery methodologies: Randomised c
Slide 13: Asset scalability & core value drivers
Asset scalability & core value drivers Premium recurring economics (All figures in A$) OncoSil Medical (ASX:OSL) presents a highly efficient, high-margin commercial investment case with a market rsonal use only capitalisation of A$25.2M. Backed by a 44% YoY increase in FY26¹ reported product revenue
Slide 14: A Natural Fit for Interventional Oncology, with Near-Term Catalysts
A Natural Fit for Interventional Oncology, with Near-Term Catalysts CT-guided Percutaneous Delivery Near-Term Catalysts rsonal use only Broader Physician Access US dCCA launch - 1H CY27 Expands the treating base to include Interventional Radiologists Up to five centres within a 30-patient FDA post-a
Slide 15: The 12-month shareholder catalyst runway
The 12-month shareholder catalyst runway Execution-driven milestones driving top-line revenue growth Key strategic catalysts: rsonal use only G-BA Trial European Label US Site Activation & Australian Commercial Commencement Expansion regulatory Revenue (1H CY27) Launch (1H CY27) (1H CY27) submission
Slide 16: For more information, please contact
rsonal use only Targeted approach • Positive impact For more information, please contact: CEO & Managing Director Nigel Lange nigel.lange@oncosil.com OncoSil Medical Limited (ASX:OSL) Level 5, 7 Eden Park Drive Macquarie Park, NSW, 2113 +61 2 8935 9629 www.investors.oncosil.com 13
OncoSil Medical — Shareholder Meeting (November 2026) on 6ix